Results 101 to 110 of about 20,060 (180)

Correction: Efficacy and safety of pegylated interferon in the treatment of JAK2^V617F-positive polycythemia vera with a dose de-escalation strategy: a single-center retrospective study. [PDF]

Front Oncol
Chang L, Li WX, Cai H, Li J, Duan MH.
europepmc   +1 more source

The safety, tolerability, pharmacokinetics, and pharmacodynamics of nebulized pegylated interferon α-2b in healthy adults: a randomized phase 1 trial. [PDF]

BMC Pharmacol Toxicol
Huang W, Kang Y, Zhao Y, Yang J, Dai C, Wu W, Xu J, Jin W, Wu X, Zhou Q.   +9 more
europepmc   +1 more source

Impact of nonalcoholic fatty liver disease on the functional cure of nucleos(t)ide analogues-treated chronic hepatitis B patients add-on pegylated interferon therapy: a retrospective study. [PDF]

PeerJ
Li H, Li L, Zhao Y, Yang G, Wang X, Fu J, Li L, Pan X.   +7 more
europepmc   +1 more source

Dystonia during pegylated interferon alpha therapy in a case with essential thrombocythemia and cerebral infarction. [PDF]

Neurol Sci
Zhang P, Han B, Meng K, Cheng X, Liu Y, Sun Y, Hu F.   +6 more
europepmc   +1 more source

Safety and efficacy of PD-1 antibody combined with pegylated interferon α for functional cure in nucleos(t)ide analogues-suppressed chronic hepatitis B patients: protocol for a multicentre randomised controlled trial. [PDF]

BMJ Open
Wang H, Li X, Lu J, Zhang X, Dang S, Li Y, He Y, Guo Y, Wang J, Maimaitijiang W, Zheng S, Ren S, Cao H, Zhang W, Zhang X, Ma H, Wang FS, Fu J.   +17 more
europepmc   +1 more source

Pegylated interferon for acute hepatitis C

Cochrane Database of Systematic Reviews, 2007
Marija Simin, Robert P Myers, Davor Štimac, Christian Gluud   +3 more
openaire   +2 more sources

Efficacy and safety of pegylated interferon in the treatment of JAK2^V617F-positive polycythemia vera with a dose de-escalation strategy: a single-center retrospective study. [PDF]

Front Oncol
Chang L, Li WX, Cai H, Li J, Duan MH.
europepmc   +1 more source

A machine learning-based predictive model for 48-week hepatitis B surface antigen seroclearance in chronic hepatitis B patients treated with pegylated interferon α-2b: prediction at week 24. [PDF]

Front Cell Dev Biol
Kong N, Wang K, Wang Y, Lou S, Zhou L, Wang T, Tan Z, Qu L.   +7 more
europepmc   +1 more source

RNA Sequencing Analysis of Patients with Chronic Hepatitis B Treated Using PEGylated Interferon. [PDF]

Int J Gen Med
Chen SL, Shen YJ, Chen GZ.
europepmc   +1 more source

Systematic review and meta-analysis: de novo combination of nucleos(t)ide analogs and pegylated interferon alpha versus pegylated interferon alpha monotherapy for the functional cure of chronic hepatitis B. [PDF]

Front Pharmacol
Wei N, Zheng B, Cai H, Li N, Yang J, Liu M.   +5 more
europepmc   +1 more source